FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2034762797> ?p ?o ?g. }

• W2034762797 endingPage "1671" @default.
• W2034762797 startingPage "1664" @default.
• W2034762797 abstract "ABSTRACT Caspofungin (CAS) is approved for second-line management of proven or probable invasive aspergillosis at a dose of 50 mg once daily (QD). Preclinical and limited clinical data support the concept of the dose-dependent antifungal efficacy of CAS with preservation of its favorable safety profile. Little is known, however, about the pharmacokinetics (PKs) of higher doses of CAS in patients. In a formal multicenter phase II dose-escalation study, CAS was administered as a 2-h infusion at doses ranging from 70 to 200 mg QD. CAS PK sampling ( n = 468 samples) was performed on day 1 and at peak and trough time points on days 4, 7, 14, and 28 (70 mg, n = 9 patients; 100 mg, n = 8 patients; 150 mg, n = 9 patients; 200 mg, n = 20 patients; total, n = 46 patients). Drug concentrations in plasma were measured by liquid chromatography tandem mass spectroscopy. Population pharmacokinetic analysis (PopPK) was performed using NONMEM (version 7) software. Model evaluation was performed using bootstrap analysis, prediction-corrected visual predictive check (pcVPC), as well as standardized visual predictive check (SVPC). The four investigated dose levels showed no difference in log-transformed dose-normalized trough levels of CAS (analysis of variance). CAS concentration data fitted best to a two-compartment model with a proportional-error model, interindividual variability (IIV) fitted best on clearance (CL), central and peripheral volume of distribution ( V 1 and V 2 , respectively) covariance fitted best on CL and V 1 , interoccasion variability (IOV) fitted best on CL, and body weight fitted best as a covariate on CL and V 1 (CL, 0.411 liters/h ± 29% IIV; IOV on CL, 16%; V 1 , 5.785 liters ± 29% IIV; intercompartmental clearance, 0.843 liters/h; V 2 , 6.53 liters ± 67% IIV). None of the other examined covariates (dose level, gender, age, serum bilirubin concentration, creatinine clearance) improved the model further. Bootstrap results showed the robustness of the final PopPK model. pcVPC and SVPC showed the predictability of the model and further confirmed the linear PKs of CAS over the dosage range of 70 to 200 mg QD. On the basis of the final model, geometric mean simulated peak plasma levels at steady state ranged from 13.8 to 39.4 mg/liter (geometric coefficient of variation, 31%), geometric mean trough levels ranged from 4.2 to 12.0 mg/liter (49%), and geometric mean areas under the concentration-time curves ranged from 170 to 487 mg · h/liter (34%) for the dosage range of 70 to 200 mg QD. CAS showed linear PKs across the investigated dosage range of 70 to 200 mg QD. Drug exposure in the present study population was comparable to that in other populations. (This study has been registered with the European Union Drug Regulating Authorities Clinical Trials website under registration no. 2006-001936-30 and at ClinicalTrials.gov under registration no. NCT00404092.)" @default.
• W2034762797 created "2016-06-24" @default.
• W2034762797 creator A5016885408 @default.
• W2034762797 creator A5028506380 @default.
• W2034762797 creator A5031047370 @default.
• W2034762797 creator A5032086305 @default.
• W2034762797 creator A5032935188 @default.
• W2034762797 creator A5044138253 @default.
• W2034762797 creator A5065221880 @default.
• W2034762797 creator A5066161797 @default.
• W2034762797 creator A5067383538 @default.
• W2034762797 creator A5070655188 @default.
• W2034762797 creator A5076077834 @default.
• W2034762797 date "2013-04-01" @default.
• W2034762797 modified "2023-09-27" @default.
• W2034762797 title "Population Pharmacokinetics of Escalating Doses of Caspofungin in a Phase II Study of Patients with Invasive Aspergillosis" @default.
• W2034762797 cites W1550111394 @default.
• W2034762797 cites W1965987183 @default.
• W2034762797 cites W1970700571 @default.
• W2034762797 cites W1973512045 @default.
• W2034762797 cites W1987415607 @default.
• W2034762797 cites W1992440113 @default.
• W2034762797 cites W1996339425 @default.
• W2034762797 cites W2026828762 @default.
• W2034762797 cites W2028808881 @default.
• W2034762797 cites W2034599708 @default.
• W2034762797 cites W2040017988 @default.
• W2034762797 cites W2058734479 @default.
• W2034762797 cites W2066464642 @default.
• W2034762797 cites W2073437339 @default.
• W2034762797 cites W2083668821 @default.
• W2034762797 cites W2087478209 @default.
• W2034762797 cites W2114146849 @default.
• W2034762797 cites W2137107343 @default.
• W2034762797 cites W2142281465 @default.
• W2034762797 cites W2146555604 @default.
• W2034762797 cites W2147467548 @default.
• W2034762797 cites W2150824761 @default.
• W2034762797 cites W2153828715 @default.
• W2034762797 cites W2154056008 @default.
• W2034762797 cites W2156228013 @default.
• W2034762797 cites W2163773890 @default.
• W2034762797 cites W2164615015 @default.
• W2034762797 cites W2167807568 @default.
• W2034762797 cites W2168334830 @default.
• W2034762797 cites W2171794072 @default.
• W2034762797 cites W2172274380 @default.
• W2034762797 cites W4237920468 @default.
• W2034762797 doi "https://doi.org/10.1128/aac.01912-12" @default.
• W2034762797 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3623320" @default.
• W2034762797 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23335740" @default.
• W2034762797 hasPublicationYear "2013" @default.
• W2034762797 type Work @default.
• W2034762797 sameAs 2034762797 @default.
• W2034762797 citedByCount "42" @default.
• W2034762797 countsByYear W20347627972014 @default.
• W2034762797 countsByYear W20347627972015 @default.
• W2034762797 countsByYear W20347627972016 @default.
• W2034762797 countsByYear W20347627972017 @default.
• W2034762797 countsByYear W20347627972018 @default.
• W2034762797 countsByYear W20347627972019 @default.
• W2034762797 countsByYear W20347627972020 @default.
• W2034762797 countsByYear W20347627972021 @default.
• W2034762797 countsByYear W20347627972022 @default.
• W2034762797 countsByYear W20347627972023 @default.
• W2034762797 crossrefType "journal-article" @default.
• W2034762797 hasAuthorship W2034762797A5016885408 @default.
• W2034762797 hasAuthorship W2034762797A5028506380 @default.
• W2034762797 hasAuthorship W2034762797A5031047370 @default.
• W2034762797 hasAuthorship W2034762797A5032086305 @default.
• W2034762797 hasAuthorship W2034762797A5032935188 @default.
• W2034762797 hasAuthorship W2034762797A5044138253 @default.
• W2034762797 hasAuthorship W2034762797A5065221880 @default.
• W2034762797 hasAuthorship W2034762797A5066161797 @default.
• W2034762797 hasAuthorship W2034762797A5067383538 @default.
• W2034762797 hasAuthorship W2034762797A5070655188 @default.
• W2034762797 hasAuthorship W2034762797A5076077834 @default.
• W2034762797 hasBestOaLocation W20347627971 @default.
• W2034762797 hasConcept C112705442 @default.
• W2034762797 hasConcept C126322002 @default.
• W2034762797 hasConcept C126894567 @default.
• W2034762797 hasConcept C139254425 @default.
• W2034762797 hasConcept C16005928 @default.
• W2034762797 hasConcept C203014093 @default.
• W2034762797 hasConcept C2776239304 @default.
• W2034762797 hasConcept C2776391196 @default.
• W2034762797 hasConcept C2777501473 @default.
• W2034762797 hasConcept C2779548794 @default.
• W2034762797 hasConcept C2780402444 @default.
• W2034762797 hasConcept C2780690907 @default.
• W2034762797 hasConcept C2908647359 @default.
• W2034762797 hasConcept C3020755252 @default.
• W2034762797 hasConcept C31760486 @default.
• W2034762797 hasConcept C535046627 @default.
• W2034762797 hasConcept C71924100 @default.
• W2034762797 hasConcept C90924648 @default.
• W2034762797 hasConcept C99454951 @default.
• W2034762797 hasConceptScore W2034762797C112705442 @default.

• next